The chronic liver diseases therapeutics market is driven by factors such as an increase in the prevalence of liver diseases, rise in alcohol consumption, and the growing aging population. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are expected to be the most common causes of chronic liver diseases in the coming years. The market is also influenced by the emergence of novel drugs, such as antifibrotics and drugs targeting the immune system, as well as increasing demand for liver transplants. However, the market faces challenges such as high treatment costs, lack of awareness about the disease, and stringent regulatory requirements. Overall, the chronic liver diseases therapeutics market is expected to grow in the coming years due to the increasing incidence of liver diseases and the development of innovative therapies.
The global Chronic Liver Diseases Therapeutics Market is estimated to be valued at US$ 15,184 million in 2022 and is expected to exhibit a CAGR of 9.5 % over the forecast period (2022-2030).
Leading Companies in the Chronic Liver Diseases Therapeutics Industry:
1. Astellas Pharma Inc.
Founded in 2005, Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo, Japan. It operates in more than 70 countries worldwide, with a focus on research and development of innovative drugs in the areas of oncology, urology, immunology, and transplantation. In March, 2023 Astellas Pharma Inc. announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar
2. Bristol-Myers Squibb
Bristol-Myers Squibb was founded in 1887 and is headquartered in New York, USA. The company operates in more than 60 countries worldwide, with a focus on research and development of drugs in the areas of oncology, immunology, cardiovascular, and fibrotic diseases. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
3. Gilead Sciences
Founded in 1987, Gilead Sciences is headquartered in California, USA. The company operates in more than 35 countries worldwide, with a focus on research and development of drugs in the areas of oncology, virology, inflammation, and respiratory diseases.
4. GlaxoSmithKline Plc
GlaxoSmithKline Plc was founded in 2000 and is headquartered in London, UK. The company operates in more than 100 countries worldwide, with a focus on research and development of drugs in the areas of respiratory, HIV/AIDS, vaccines, and oncology. In March, 2023 GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
5. F. Hoffmann-La Roche Ltd.
Founded in 1896, F. Hoffmann-La Roche Ltd. is headquartered in Basel, Switzerland. The company operates in more than 150 countries worldwide, with a focus on research and development of drugs in the areas of oncology, neuroscience, ophthalmology, and infectious diseases.
6. Merck & Co. Inc.
Merck & Co. Inc. was founded in 1891 and is headquartered in New Jersey, USA. The company operates in more than 140 countries worldwide, with a focus on research and development of drugs in the areas of oncology, vaccines, infectious diseases, and cardiovascular diseases. In November, 2021 Merck & Co. Inc. announced that the US Food and Drug Administration (FDA) had granted the company's investigational HIV-1 capsid inhibitor, MK-8718, Breakthrough Therapy designation for the treatment of people living with HIV-1 who have highly resistant strains of the virus.
7. Novartis AG
Founded in 1996, Novartis AG is headquartered in Basel, Switzerland. The company operates in more than 140 countries worldwide, with a focus on research and development of drugs in the areas of oncology, immunology, neuroscience, and ophthalmology. In March, 2023 Sandoz, the global leader in off-patent medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.
8. Sanofi S.A
Sanofi S.A was founded in 1973 and is headquartered in Paris, France. The company operates in more than 170 countries worldwide, with a focus on research and development of drugs in the areas of oncology, diabetes, cardiovascular diseases, and vaccines. In March, 2023 Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded Biopharmaceutical Company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
9. Pfizer Inc.
Founded in 1849, Pfizer Inc. is headquartered in New York, USA. The company operates in more than 175 countries worldwide, with a focus on research and development of drugs in the areas of oncology, immunology, vaccines, and rare diseases. In March, 2023 Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age (also referred to as under 5 years of age) at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine.
10. Takeda Pharmaceutical
Takeda Pharmaceutical was founded in 1781 and is headquartered in Osaka, Japan. The company operates in more than 80 countries worldwide, with a focus on research and development of drugs in the areas of gastroenterology, oncology, neuroscience, and rare diseases. In September 2021, Takeda announced positive results from a Phase 3 trial of its oral plasma kallikrein inhibitor, TAK-994, for the treatment of hereditary angioedema (HAE).
11. Valeant Pharmaceuticals
Valeant Pharmaceuticals was founded in 1960 and is headquartered in Quebec, Canada. The company operates in more than 100 countries worldwide, with a focus on research and development of drugs in the areas of dermatology, gastrointestinal disorders, and ophthalmology.
12. Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. was founded in 1984 and is headquartered in New Jersey, USA. The company operates in more than 40 countries worldwide, with a focus on research and development of generic and branded pharmaceuticals in a wide range of therapeutic areas.
*Definition- Chronic liver diseases therapeutics refers to the drugs and treatments used to manage and treat long-term liver diseases such as hepatitis, cirrhosis, and liver cancer. The aim is to reduce inflammation, prevent further damage, and improve liver function.
